Announced Fri, 4 Sept · 11:37 IST
FY2025-26 annual report and 38th AGM notice
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+6.3%1-day move
₹374.10
prior close
₹380.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2-0.0+0.9+6.3+6.5+9.5+11.2+24.6+7.8————
Up moveDown movePending
AI summary
SMS Pharma's FY2025-26 report records Rs 887 crore revenue, Rs 171 crore EBITDA and Rs 102 crore profit after tax, up 13 percent, 23 percent and 47 percent. It plans Rs 280 crore of expansion by FY27, including 9,600 metric tonnes per year of ibuprofen capacity. The 38th AGM is on 29 September 2026 at 10:30 a.m. online; e-voting runs 25 to 28 September.
Likely market impact
Strong profit growth and expansion may aid the stock, but returns depend on timely project completion, new product sales and stable supply chains.